528 material Form 8-K filings that 462 companies we cover made with the SEC in January 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Merit Medical said preliminary unaudited revenue for the year ended December 31, 2024 is about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% from the prior year. The figures are unaudited and may change after the audit, and the company plans to report full fourth-quarter and 2024 results and 2025 guidance on February 25, 2025.
Preliminary 2024 revenue of about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% year over year
Preliminary constant currency revenue increased about 8.4% to 8.6%; the foreign exchange impact is $7.9 million
Audited results are not yet available, and the auditor has not reviewed the preliminary figures
Full 2024 results and fiscal 2025 guidance are scheduled for February 25, 2025 after market close
Exelixis reported preliminary, unaudited fiscal 2024 results and gave 2025 guidance, with total revenues of about $2.165 billion and net product revenues of about $1.805 billion for 2024. The audit is ongoing and the figures could change, with audited results due February 11, 2025. The 2025 net product revenue guidance of $1.95 billion to $2.05 billion sits above the 2024 preliminary figure, which points to expected growth for the cabozantinib franchise.
Preliminary fiscal 2024 total revenues of about $2.165 billion and net product revenues of about $1.805 billion
2025 guidance: total revenues of $2.15 billion to $2.25 billion; net product revenues of $1.95 billion to $2.05 billion
2025 research and development expenses guided at $925 million to $975 million; SG&A at $475 million to $525 million
Audited fiscal 2024 results scheduled for release February 11, 2025; the figures could change before then
PTC Therapeutics reported preliminary, unaudited 2024 total revenue of approximately $814 million, which the company said exceeded its guidance, and gave 2025 total revenue guidance of $600 million to $800 million. The 2025 range sits below the 2024 preliminary figure, and the 2024 numbers remain subject to the year-end audit.
Unaudited 2024 total net revenue of approximately $814 million; net product revenue approximately $601 million
Translarna approximately $340 million and Emflaza approximately $207 million in unaudited 2024 net product revenue; Evrysdi royalty revenue approximately $211 million
2025 guidance: total revenue $600 million to $800 million; GAAP R&D and SG&A expense $805 million to $835 million
Results will be presented at the J.P. Morgan Healthcare Conference on January 13, 2025, after which the company enters a quiet period
Ichor Holdings said preliminary fourth quarter 2024 revenue of approximately $233 million was at the high end of its guidance, but expects gross margin and earnings per share to fall below the low end of prior guidance ranges. The company cited higher labor costs, higher-than-anticipated inventory charges and unfavorable product mix, and it now expects first quarter 2025 revenue of $235 million to $250 million and 2025 revenue above current expectations. The results are preliminary, unaudited and subject to completion of audit procedures, and the 10-K for fiscal 2024 has not been filed.
Q4 2024 revenue of approximately $233 million, at the high end of guidance and up over 10% sequentially from Q3 2024
Q4 2024 gross margin of 11% to 12% on a GAAP basis and about 12% non-GAAP; EPS below prior guidance ranges
Q1 2025 revenue outlook of $235 million to $250 million, with gross margin returning to 13% to 15%
Full Q4 and fiscal 2024 results and conference call on February 4, 2025, at 1:30 p.m. PT
Xencor said its preliminary, unaudited cash, cash equivalents and marketable debt securities were about $707 million at December 31, 2024, compared with $697.0 million a year earlier. The company expects this cash to fund research and development and operations into 2028, and the figures may change after year-end closing and audit procedures.
Preliminary, unaudited cash, cash equivalents and marketable debt securities of about $707 million at December 31, 2024, versus $697.0 million at December 31, 2023
Based on current operating plans, Xencor expects cash to fund research and development programs and operations into 2028
January 13, 2025 investor presentation also updated XmAb808 to resumed dose escalation and reported completed enrollment in three vudalimab studies
Revvity said preliminary fourth-quarter 2024 revenue growth of about 5% reported and 6% organic, which it expects to produce revenue of about $730 million. It also now expects full-year 2024 adjusted earnings per share to meet or exceed guidance given on November 4, 2024. Full results are due before market open on January 31, 2025.
Q4 2024 reported revenue growth expected at about 5%, organic growth about 6%
Q4 2024 revenue expected at approximately $730 million
Full-year 2024 adjusted EPS expected to meet or exceed the November 4, 2024 guidance
Full Q4 and full-year 2024 results and earnings call on January 31, 2025; CEO Prahlad Singh presents at J.P. Morgan Healthcare Conference on January 13, 2025
Shake Shack reported preliminary, unaudited fourth-quarter and fiscal 2024 results, with fourth-quarter total revenue of $328.7 million, up 14.8%, and Adjusted EBITDA of $46.5 million, up 48% year over year. The company also gave initial 2025 guidance of $1.45 billion to $1.48 billion in total revenue and $200 million to $210 million in Adjusted EBITDA, and said it now sees its Company-operated footprint reaching at least 1,500 Shacks over time, up from a prior target of 450.
Q4 2024 total revenue $328.7 million; FY2024 total revenue $1.3 billion; same-Shack sales up 4.3% in Q4
Q4 2024 Adjusted EBITDA $46.5 million, up 48%; restaurant-level profit margin about 22.7% of Shack sales
2025 guidance: total revenue $1.45 billion to $1.48 billion; Adjusted EBITDA $200 million to $210 million; net income $45 million to $60 million
Long-term Company-operated Shack target raised to at least 1,500 from 450; results are preliminary and unaudited pending the Form 10-K
ADMA Biologics preliminarily estimated unaudited total 2024 revenue of $417-425 million, above its previous guidance of $415 million, and said year-end 2024 cash grew to more than $100 million. The company also expects 2025 total revenue above $485 million and net income above $170 million, which gives shareholders updated figures for the year ahead.
Preliminary unaudited FY 2024 total revenue of $417-425 million, versus previous guidance of $415 million
Year-end 2024 total cash above $100 million, up about $45 million quarter over quarter, after $30 million of debt discharged in Q4 2024
FY 2025 total revenue expected to exceed $485 million and net income to exceed $170 million; FY 2026 revenue expected above $600 million
PAS submitted to the FDA for yield enhancement production process; approval anticipated mid-2025
Option Care Health reported preliminary, unaudited fourth-quarter and full-year 2024 results, with full-year net revenue of about $4.99 billion to $5.00 billion, up 16.0% to 16.2%, and adjusted diluted EPS of $1.55 to $1.59. For 2025 it expects net revenue of $5.2 billion to $5.4 billion and adjusted EPS of $1.59 to $1.69, including a $60 million to $70 million gross profit reduction tied to Stelara pricing adjustments. The Board also approved a new $500 million share repurchase program with no specified expiration date.
Q4 2024 net revenue of about $1.34 billion to $1.35 billion, up 19.2% to 20.1% year over year
Full-year 2024 adjusted diluted EPS of $1.55 to $1.59; GAAP diluted EPS of $1.21 to $1.23
2025 guidance: net revenue of $5.2 billion to $5.4 billion and adjusted EBITDA of $445 million to $465 million
New $500 million share repurchase program approved January 10, 2025; full results due February 26, 2025
Papa John's released preliminary, unaudited sales and unit development figures for the fourth quarter and full year 2024, ahead of an investor conference. Global system-wide sales fell about 3% for the year, and North America comparable sales declined 4%, so the results show weaker sales. Final results are due before the market opens on February 27, 2025.
Full-year 2024 global system-wide sales were about $4.9 billion, down about 3% from 2023, and down about 1% excluding the 53rd week in 2023.
North America comparable sales were down 4% for the full year and down 4% in the fourth quarter.
International comparable sales were up 2% in the fourth quarter but down less than 1% for the full year.
The company had 124 net new restaurants in 2024, and final results are scheduled for February 27, 2025.
Inspire Medical Systems reported preliminary, unaudited fourth-quarter 2024 revenue of $239.5 million to $239.7 million, about 25% higher than a year earlier, and full-year 2024 revenue of $802.6 million to $802.8 million, up about 28%. The company also gave initial 2025 revenue guidance of $940 million to $955 million, a 17% to 19% increase, and announced leadership changes, including a new Chief Manufacturing and Quality Officer. The figures are estimates that may change before the full 2024 results are reported in the Form 10-K.
Preliminary Q4 2024 revenue of $239.5 million to $239.7 million, up about 25% year over year
Preliminary full-year 2024 revenue of $802.6 million to $802.8 million, up about 28%
Initial 2025 revenue guidance of $940 million to $955 million, a 17% to 19% increase
Jason Kelly named Chief Manufacturing and Quality Officer effective January 20, 2025; Chief Medical Officer Charisse Sparks left the company at the beginning of 2025
Regeneron released preliminary, unaudited fourth-quarter and full-year 2024 figures at the J.P. Morgan Healthcare Conference, showing aggregate U.S. EYLEA net product sales of $6 billion for the year, up 1%. The company also expects a fourth-quarter acquired in-process R&D charge of approximately $14 million pre-tax, which it says will reduce GAAP and non-GAAP net income per diluted share by about $0.11, and notes that results have not been finalized.
EYLEA HD and EYLEA aggregate U.S. net product sales were $6 billion for 2024, up 1%, and $1.5 billion in the fourth quarter of 2024 (preliminary, unaudited).
Expected fourth-quarter 2024 acquired IPR&D charge of approximately $14 million pre-tax, primarily related to asset acquisitions.
The charge is expected to lower GAAP and non-GAAP net income per diluted share for Q4 2024 by approximately $0.11.
Libtayo exceeded $1 billion in 2024 annual net sales, according to the press release.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.